For thousands of people living with multiple sclerosis (MS) in England, a new hope has emerged as the NHS makes fampridine available. This 'signal booster' medication has long been used by those who can afford it privately, but its introduction on the NHS will make a significant difference to many struggling with MS-related mobility issues.
Multiple sclerosis is a complex neurological condition where the body's immune system mistakenly attacks the protective covering around nerve cells, disrupting electrical messages from the brain. This damage affects muscle control and walking, causing debilitating symptoms for those affected. Fampridine works by enhancing these impaired signals, making it easier to move and carry out daily activities.
With over 120,000 people living with MS in England, approximately 5,000 individuals per year are expected to be eligible for fampridine, based on their walking difficulties. Clinical trials have shown promising results, with around four in ten patients experiencing improvements in both walking speed and distance covered. For many, this could translate into greater freedom within their homes, increased confidence, and a better quality of life.
The NHS's decision to make fampridine available follows a previous assessment that deemed it not to offer sufficient value for money. However, with its introduction now in line with the rest of the UK, patients will be able to access this medication. Initially, those prescribed will receive it for up to a month, and only those who demonstrate a clear benefit will be able to continue treatment long-term.
Aysen Slack, 65, from Eastbourne, had previously paid privately for fampridine but was unable to sustain the cost. She described the medication as 'working well' for her and expressed her desire to try it again, highlighting that her mobility had significantly decreased. Prof Frankie Swords noted even modest improvements could be 'life-changing', enhancing patients' ability to navigate their homes and engage more confidently with the outside world.
Ceri Smith from the MS Society welcomed the news, stating the drug's potential to enable greater independence and support continued employment for many. This development brings hope and new possibilities for those affected by MS in England, building on existing treatments like physiotherapy and walking aids.